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Abstract 
Mutations of p53 in cancer can result in a gain-of-function (GOF) associated with 
tumour progression and metastasis. We show that inducible expression of several p53 
“hotspot” mutants promote a range of centrosome abnormalities including centrosome 
amplification, increased centrosome size and loss of cohesion, which lead to mitotic 
defects and multinucleation. These mutant p53 expressing cells also exhibit a change 
in morphology and enhanced invasive capabilities. Consequently, we sought for a 
means to specifically target the function of mutant p53 in cancer cells. This study has 
identified ANKRD11 as a key regulator of the oncogenic potential of mutant p53. 
Loss of expression of ANKRD11 with p53 mutation defines breast cancer patients 
with poor prognosis. ANKRD11 alleviates the mitotic defects driven by mutant p53 
and suppresses mutant p53-mediated mesenchymal-like transformation and invasion. 
Mechanistically, we show that ANKRD11 restores a native conformation to the 
mutant p53 protein and causes dissociation of the mutant p53•p63 complex. This 
represents the first evidence of an endogenous protein with the capacity to suppress 











The p53 protein is a tumour suppressor that predominantly functions as a 
sequence-specific transcription factor regulating the expression of various target 
genes involved in cell-cycle arrest, apoptosis, senescence, DNA repair, and inhibition 
of angiogenesis and metastasis, in response to a variety of cellular insults (Lane 1992, 
Liu and Chen 2006). Approximately 50% of all human cancers contain a mutation in 
the TP53 gene (Hollstein et al 1991, Vogelstein et al 2000) with the majority of these 
mutations occurring within the DNA-binding domain (DBD) (Bullock and Fersht 
2001, Olivier et al 2010). Mutations at six specific residues in the DBD have been 
identified as mutational “hotspots” and are classified into two categories: DNA 
contact mutants (R248Q, R248W, R273C and R273H) involving residues which 
specifically interact with DNA, and structural mutants (R175H, G245S, R249S and 
R282W) which exhibit local or global distortions of the p53 protein structure (Cho et 
al 1994). 
 
Mutant p53 proteins exhibit both loss- and gain-of-function characteristics. 
Loss-of-function is largely due to the inability of mutant p53 to bind the canonical 
wild-type p53 binding site, resulting in an inability to transactivate its target genes 
(Kato et al 2003, Scian et al 2004), an attenuated tumour suppressive function and 
consequently, deregulated cellular growth and apoptosis. In contrast, gain-of-function 
(GOF) characteristics of mutant p53 are critical for tumour progression and metastasis 
(Brosh and Rotter 2009, Oren and Rotter 2010). A variety of GOF phenotypes of 
mutant p53 have been reported including increased invasive and metastatic potential 
of cells, resistance to chemotherapies, regulation of pro-inflammatory and anti-
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apoptotic pathways and increased genomic instability (Oren and Rotter 2010), all of 
which give mutant p53 expressing cells a selective growth and survival advantage.  
 
Various strategies have been developed to target mutant p53 in cancers 
including small molecules that aim to restore the native conformation to the unfolded 
mutant p53 proteins (Bykov et al 2002), or target their interactions with family 
members (Di Agostino et al 2008, Kravchenko et al 2008). Using a novel protein-
based approach, we have previously shown that ANKRD11 can restore normal 
transactivation potential to a p53 hotspot mutant in a breast cancer cell line (Neilsen et 
al 2008), and represents the first endogenously-expressed protein with a capacity to 
rescue mutant p53 function. In this study we utilised a panel of ecdysone-inducible 
cell lines in a p53 null background to express various p53 hotspot mutants to 
investigate cellular processes that are driven by mutant p53 GOF and which can be 














p53 mutation and loss of ANKRD11 expression define cancer patients with poor 
prognosis 
Previously, we established that ANKRD11 could restore normal 
transactivation potential to the p53-R273H mutant (Neilsen et al 2008) and thus we 
explored a wider role for ANKRD11 in the suppression of the oncogenic functions of 
mutant p53. ANKRD11 was robustly expressed in the normal breast epithelium, 
however was down-regulated in the majority of breast tumours (Fig. 1A). Analysis of 
the expression profiling of a cohort of breast tumours (Miller et al 2005) revealed that 
the combination of p53 mutation and loss of ANKRD11 expression defined a subset 
of patients with poor outcomes (Fig. 1B). Low ANKRD11 expression was also 
significantly associated with poor survival in cohorts of bladder and lung tumours 
(Supp. Fig. S1). Furthermore, loss of ANKRD11 expression was significantly 
associated with invasion to the lymph nodes in breast tumours expressing mutant p53 
(Fig. 1C). Collectively, the data support a role for ANKRD11 as a suppressor of the 
oncogenic potential of mutant p53. We subsequently sought to understand the 
mechanism of this suppression. 
 
Mutant p53 drives centrosome abnormalities and multinucleation that can be 
suppressed by ANKRD11 
Several biological pathways were examined to assess mutant p53 GOF. These 
assays were based on the inducible expression of mutant p53 in the H1299 p53-null 
genetic background. In these cell lines, p53 can be expressed dose-dependent to the 
inducing agent, Ponasterone A (PonA). Furthermore, the inducible expression of 
wild-type p53 was equivalent to DNA damage induced activation of the p53 pathway, 
 6
and mutant p53 levels comparable to endogenous mutant p53 expression in cancer 
cell lines (Supp. Fig. S2).  
 
Induction of mutant p53 in H1299 cells resulted in a time-dependent increase 
in multinucleation, with approximately 25% of cells exhibiting more than one nuclei 
following 96 hours of mutant p53 expression (Fig. 2A). Giant multinucleated H1299 
cells were observed following prolonged expression of mutant p53 (Supp. Fig. S3A). 
Co-staining cells for α-tubulin and γ-tubulin, markers for microtubules and 
centrosomes respectively, showed induction of mutant p53 was associated with a 
small but significant increase in the number of centrosomes per cell (Fig 2B). The 
limited size of the increase was most likely due to the small number of cell cycles 
observed. Centrin immunofluorescence studies demonstrated that these aberrant 
centrosomal frequencies were not due to centriole splitting (Supp. Fig. S3B). 
However, there was a significant increase in average centrosome size (Fig. 2C), which 
was not due to increased γ-tubulin expression (Supp. Fig. S3B) A significant increase 
in the average distance between centrosomes was also observed (Fig. 2D). These 
observations are demonstrated as bone fide mutant p53 GOF pathways as 
multinucleation and centrosomal aberrations were not observed in cells with induced 
wild-type p53 (Fig. 2A-D), and importantly multinucleation of EI-H1299 cells was 
not observed following treatment with PonA (Supp. Fig. S4). Furthermore, at 24 
hours post-induction cells were observed with centrosomal amplification without 
multinucleation, suggesting that the defects in centrosomal duplication are driving the 
multinucleation phenotype and not mitotic failure. 
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To examine how the restored expression of ANKRD11 would impact upon the 
ability of mutant p53 to disrupt normal mitotic fidelity, ANKRD11 was stably-
expressed in EI p53 mutant cells (which exhibit undetectable ANKRD11 expression) 
to approximate physiological levels, as judged by the levels observed in primary 
epithelial cells (Supp. Fig. S5). Restoring ANKRD11 expression completely 
abolished the ability of induced p53-R175H to drive multinucleation in EI p53-
R175H cells (Fig. 2A). A similar result was also seen following induction of p53-
R248W in the presence of ANKRD11 expression (Supp. Fig. S6). Furthermore, 
induction of p53-R175H failed to modulate centrosome size, separation or cohesion in 
the presence of restored ANKRD11 expression (Fig. 2B-D). Importantly, ANKRD11 
did not influence p53-R175H mutant protein levels following exposure to the 
inducing agent, PonA (Fig. 2E). Together these findings illustrate the capacity of 
ANKRD11 to suppress the oncogenic potential of a p53 GOF mutant. 
 
Mutant p53 expression is associated with chromosome segregation defects that 
can be suppressed by ANKRD11 
As centrosome abnormalities have previously been linked to aberrant mitotic 
progression (Mailand et al 2002, Wonsey and Follettie 2005), we next examined the 
mutant p53 expressing cells ability to undergo mitosis. The defects in centrosome 
duplication and segregation in the induced mutant p53 cells was associated with a 20 
to 30% increase in the frequency of abnormal mitotic spindles (Fig. 3A & B), and a 
significant increase in cells with lagging chromosomes (Fig. 3C) and anaphase 
bridges (Fig. 3D) compared with uninduced cells. The duration of mitosis, as assessed 
by live cell imaging, showed mutant p53 cells slowed the progression through mitosis 
to 72-75 mins (p<0.03) compared with 57-58 minutes in uninduced H1299 cells (Fig. 
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3E, Movies S1-S6). These findings show that mutant p53 expression does impact 
upon the normal execution of mitosis. 
 
In the presence of restored ANKRD11 expression, the ability of induced p53-
R175H to drive the formation of abnormal spindles, lagging chromosomes and 
anaphase bridges was completely ablated (Fig. 3A-D). Furthermore, the induced EI 
p53-R175H cells expressing ANKRD11 exhibited an average of 60 minutes in mitosis 
as compared to 75 minutes for induced p53-R175H alone (Fig. 3E, Movies S7-S8). 
These observations indicate that p53 mutants cannot drive tumourigenesis in the 
presence of physiological levels of ANKRD11. 
 
Mutant p53 induces a mesenchymal morphology that is suppressed by 
ANKRD11 
Gene expression arrays were used to determine the specific genes and 
pathways regulated upon induction of the p53-R175H mutant (Table 1). Following 
analysis of microarray expression data, Ingenuity Pathway Analysis revealed that 
many of the genes regulated by p53-R175H were shared across multiple biological 
pathways, which converged towards a network involved in cell motility and cell-to-
cell signaling/interaction (Table 1, Supp. Fig. S7). Consequently, we investigated if 
induction of mutant p53 affected colony formation and morphology of epithelial 
H1299 cells. Control H1299 cells grew from single cells as tight colonies with defined 
boundaries, typical of epithelial cells (Fig. 4A, left). Upon induction of a structural 
(R175H) or DNA contact (R248Q) mutant, cells acquired an elongated mesenchymal-
like morphology and exhibited disordered growth and decreased colony density (Fig. 
4A, middle). In addition, ZO-1 immunofluorescence of EI p53-R175H cells showed 
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that cells dissociated from each other within 16 hours of p53-R175H induction (Fig. 
4B), which is indicative of an invasive phenotype. 
 
As we had already shown that ANKRD11 could alleviate the mitotic defects 
caused by mutant p53 induction, we next aimed to determine if the mesenchymal-like 
morphology of mutant p53-expressing cells could also be suppressed by ANKRD11. 
Physiological ANKRD11 expression in EI p53-R175H cells suppressed the 
mesenchymal-like phenotype, as demonstrated by a retention of tight colony 
formation following p53-R175H induction (Fig. 4A, right & Fig. 4B). Stable 
ANKRD11 expression in EI p53-R248Q cells also resulted in a restoration of the 
epithelial-like phenotype (Fig. 4A, right).  
 
ANKRD11 suppresses mutant p53 invasive GOF 
Mutant p53 GOF plays a key role in tumour progression, particularly through 
migration, invasion and metastasis. As induction of p53-R175H gave rise to an 
invasive phenotype, we aimed to determine if this was associated with an increased 
invasive capacity. The ability of uninduced or induced cells to invade through 
matrigel toward a chemo-attractant was measured in real-time using the Xcelligence 
system. Induction of p53-R175H did indeed result in an enhanced invasive capacity of 
H1299 cells, as demonstrated by a 2.5-fold (p<0.05) increased rate of invasion (Fig. 
5). Stable expression of ANKRD11 in this system also ablated the ability of the 
induced R175H mutant to drive invasion (Fig. 5). Importantly, we also demonstrate 
that ANKRD11 can influence the tumorigenic properties of an additional mutant p53-
expressing cancer cell line, MDA-MB-468 (p53 R273H). Expression of ANKRD11 in 
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this cell line was shown to slow the rate of migration of the MDA-MB-468 breast 
cancer cell line in a mutant p53-dependent manner (Supp. Fig. S8). 
 
ANKRD11 restores a wild-type conformation and function to the p53-R175H 
mutant protein 
We speculate that ANKRD11 can restore normal p53 function to p53 mutants 
as a consequence of its ability to directly interact with the mutant p53 proteins and 
revert the protein to a wild-type p53 conformation. We have previously shown the 
ankyrin repeat domain (ANKRD11144-288aa) to directly interact with wild-type p53 
(Neilsen et al 2008). We confirmed through co-immunoprecipitation assays that 
ANKRD11144-288aa could interact with both wild-type and eight p53 hotspot mutants 
(Fig. 6A). Further to these findings, we identified the C-terminus of p53 (p53325-393aa) 
as the minimal region required for interaction with the ankyrin domain of ANKRD11 
(Supp. Fig. S9). 
 
To test the ability of ANKRD11 to affect mutant p53 tertiary structure, we 
utilised the conformation specific p53 antibody PAb1620 which recognises the wild-
type p53 native protein structure under non-denaturing conditions (Milner et al 1987). 
In the presence of ANKRD11, induced p53-R175H exhibited an enhanced binding to 
the PAb1620 antibody, in comparison to that observed in the absence of ANKRD11 
(Fig. 6B). These data suggest the association of ANKRD11 with p53-R175H restores 
the mutant protein conformation to more closely resemble the wild-type protein, thus 
facilitating recognition by the PAb1620 antibody. This newly adopted ‘wild-type’ 
conformation of the mutant p53 protein was also associated with restoration of p53 
target gene expression by the p53 mutant to a level similar to that achievable by wild-
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type p53 (Supp. Fig. S10). This restoration of transcriptional activity to the mutant 
p53 protein is also accompanied by a reduction in the percentage of cells undergoing 
mitosis, as demonstrated by MPM2 staining. Induction of wild-type p53 leads to a 
65% reduction in cells undergoing mitosis (p<0.01) which is not seen following 
induction of various mutant p53 proteins. However, in the presence of ANKRD11, 
induction of the p53-R175H mutant leads to a significant (p<0.01) reduction in cells 
in mitosis (Supp. Fig. S11).  
 
ANKRD11 impedes mutant p53-p63 and mutant p53-p73 complex formation 
Previous studies have established that wild-type p53 does not interact with p63 
and p73 while p53 mutants, including R175H, R249S and R273H exhibit GOF 
interactions with p63 and p73 (Gaiddon et al 2001, Strano et al 2000, Strano et al 
2002). Immunoprecipitation in H1299 cells of co-transfected TAp63 and p53 mutants, 
including the eight p53 hotspot mutants, encompassing both DNA contact (R248Q, 
R248W, R273C and R273H) and structural (R175H, G245S, R249S, R282W) 
mutants suggest that p63 was primarily sequestered by p53 structural mutants (Fig. 
7A). The DNA contact mutant p53-R273H also weakly co-precipitated with p63, 
which is consistent with previously published reports, while the remaining three DNA 
contact mutants did not interact (Fig. 7A). The same subset of p53 mutants that 
interacted with p63 were also shown to form a complex with TAp73 (Fig. 7B). Since 
the interaction between mutant p53 and p63 contributes to the invasive GOF of 
mutant p53 in H1299 cells (Muller et al 2009) we speculated that the suppressive 
functions of ANKRD11 are due, in part, to an interference with mutant p53•p63 
complex formation.  
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Immunoprecipitation results demonstrated the formation of an R175H•p63 
complex in the absence of ANKRD11 (Fig. 7C, lane 7). However, expression of the 
complete ankyrin domain (ANKRD11144-288aa) resulted in dissociation of the 
R175H•p63 complex by up to 62 % (Fig. 7C, lane 8). ANKRD11144-288aa was also co-
expressed with p53-R175H and p73 in the same system, and the interaction between 
R175H and p73 was reduced to 56% of the base-line (Fig. 7D). These results indicate 
that the association of ANKRD11 with mutant p53 disrupts its ability to interact with 
both p63 and p73. Further immunoprecipitation experiments with various regions 
encompassing the five ankyrin repeats present in ANKRD11 enabled the region of the 
domain that disrupts the mutant p53•p63 interaction to be defined. Ankyrin repeats 
one to three dissociated the p53-R175H•p63 complex by approximately 54% (Fig. 7C, 
lane 9). The R175H•p63 interaction was, however, maintained in the presence of 
ankyrin repeats four and five (Fig. 7C, lane 10). Expression of the first ankyrin repeat 
did not dissociate the R175H•p63 complex, however expression of repeats two and 
three resulted in a 21% decrease in the observed interaction between p53-R175H and 
p63 (Supp. Fig. S12). It was therefore inferred that an 80 amino acid region of 
ANKRD11 (ANKRD11144-288aa) dissociated the R175H•p63 complex, with a slight 
reduction in complex formation also observed following co-expression of a 50 amino 









Our current understanding of the GOF properties of mutant p53 is largely 
based on studies involving stable expression of p53 mutants in a p53 null background 
(Dong et al 2009, Muller et al 2009) or mutant p53 knock-in transgenic animal 
models (Song et al 2007). These systems have proven useful to functionally 
characterise the persistent, long-term oncogenic properties of mutant p53 such as 
invasion, metastasis and large-scale genetic abnormalities. However, using the 
ecdysone-inducible system, we have been able to directly investigate the primary 
pathways that are initiated by mutant p53 expression and which ultimately lead to its 
GOF, as well as identify ANKRD11 as an endogenously expressed protein capable of 
suppressing mutant p53 GOF. 
 
Knockdown of endogenous mutant p53 in MDA-MB-468 cells results in 
reduced metastasis in a mouse model (Adorno et al 2009). Expression of ANKRD11 
in MDA-MB-468 cells also significantly reduced their ability to form colonies on 
plastic (Neilsen et al 2008). Furthermore, loss of ANKRD11 expression with p53 
mutation defines breast cancer patients with invasive tumours and poor prognosis 
(Fig. 1). Low ANKRD11 expression is also correlated with poor 5-year survival in 
bladder and lung cancer patients (Supp. Fig. S1). Loss-of-heterozygosity of 
chromosome 16q24 (the genomic location of the ANKRD11 gene) is associated with 
good prognosis in breast cancer patients (Hansen et al 1998), therefore the 
observation that survival is higher in the wild-type p53 expressing breast tumours 
with low ANKRD11 expression may be an artefact of the loss of the 16q genomic 
region and not specific to ANKRD11. The correlation of low ANKRD11 expression 
and poor survival in mutant p53 expressing breast tumours support a role for 
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ANKRD11 as a suppressor of the oncogenic potential of mutant p53. Using the 
ecdysone-inducible system, we established three biological assays for investigating 
mutant p53 GOF and the effect of ANKRD11 on these processes. Specifically we 
investigated mitotic defects arising from centrosome abnormalities, cellular 
morphology changes and invasion. 
 
Taking this approach, we show inducible expression of three p53 ‘hotspot’ 
mutants result in multinucleation, centrosome aberrations, and a significant increase 
in the percentage of cells with abnormal spindles (Fig. 2 & 3). Previous studies link 
aberrant centrosomes to both defective mitosis (Mailand et al 2002) and 
multinucleation (Wonsey and Follettie 2005), both of which we show to occur 
following mutant p53 induction. The increased distance observed between 
centrosomes in mutant p53 expressing cells may be due to de-regulation of β-catenin 
as wild-type p53 inhibits β-catenin, with high β-catenin levels associated with mutant 
p53 expression and centrosome splitting (Hadjihannas et al 2010, Sadot et al 2001). 
 
 Our findings are consistent with observations of mutant p53 GOF in mouse 
models where the expression of the mouse R172H mutant (equivalent to human 
R175H) results in tumours exhibiting centrosome amplification and an associated 
aneuploidy (Caulin et al 2007, Hingorani et al 2005, Murphy et al 2000). However, 
these previous reports are confounded as they use a K-RasG12D mutation as an 
initiating oncogenic event (Caulin et al 2007, Hingorani et al 2005). Our data shows 
that mutant p53 alone is sufficient to drive the observed GOF phenotype. These 
mitotic defects would provide a likely origin for chromosomal instability, a common 
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feature of many human tumours, which promotes metastases and is correlated with 
poor patient prognosis (Kuukasjarvi et al 1997, Rajagopalan and Lengauer 2004). 
 
This study has uncovered several novel genes and biological processes 
regulated by mutant p53 that regulate cellular movement and cell-to-cell signaling and 
interaction (Table 1). R175H has previously been shown to reprogram the cellular 
transcriptome through recruitment to novel target genes by various transcription 
factors, such as NF-Y (Di Agostino et al 2006), VDR (Stambolsky et al 2010) and 
NF-κβ (Schneider et al 2010). Indeed, our pathway analysis also showed that the NF-
κβ signaling pathway was strongly up-regulated upon induced expression of p53-
R175H (Figure S5B), further confirming a role for NF-κβ in the GOF of mutant p53 
(Weisz et al 2007). Interestingly, several integrins (ITGA3 and ITGB3) were also up-
regulated upon induction of p53-R175H consistent with a previously observed role for 
integrin recycling in the oncogenic GOF of mutant p53 (Muller et al 2009). 
 
It has previously been shown that H1299 cells with inducible expression of 
p53-R175H exhibit a mesenchymal-like phenotype following TGFβ treatment 
(Adorno et al 2009). We observe this morphological change upon induction of both 
structural (R175H) and DNA contact (R248Q) p53 mutants with no additional 
treatment (Fig. 4A). Variations in cell density may account for this contradiction to 
previous data, as cells plated at higher densities did not exhibit this phenotype 
following mutant p53 induction (data not shown). 
 
Mutant p53 GOF activity results in enhanced cellular migration, invasion and 
metastasis. We demonstrate that stable expression of ANKRD11 in the EI p53-R175H 
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cell line can suppress mutant p53-dependent invasion (Fig. 5). Furthermore, 
ANKRD11 is demonstrated to reduce the rate of migration of the MDA-MB-468 
breast cancer cell line, expressing the endogenous p53-R273H mutant, in a mutant 
p53-dependent manner (Supp. Fig. S8). Silencing of mutant p53 expression has no 
effect on cell migration, which is consistent with previous reports showing that 
silencing of endogenous mutant p53 expression alone does not alter cellular migration 
in the MDA-MB-231 breast cancer cell line (Adorno et al 2009). However, expression 
of wild-type p53 has been demonstrated to inhibit cell migration (Gadea et al 2002, 
Roger et al 2006). Therefore, the observation that stable ANKRD11 expression can 
decrease the rate of cell migration in a mutant p53-dependent manner is likely due to 
a restoration of wild-type like activity to the endogenous p53 mutant, as previously 
described (Neilsen et al 2008). 
 
For each of the assays described, the expression of ANKRD11 with induced 
mutant p53 restores the cellular phenotype to that seen in the uninduced state i.e. 
ANKRD11 suppresses the GOF of mutant p53. We have also established that 
ANKRD11 can restore wild-type p53 activity to p53 mutants. These data represent 
the first reported evidence of an endogenously expressed protein that has the capacity 
to suppress mutant p53 GOF as well as restore transcriptional activity to a p53 mutant 
(Neilsen et al 2008). This has broad implications for the development of new cancer 
therapies designed to target this pathway, as these may result not only in suppression 
of the invasive and metastatic properties of mutant p53 tumours, but also prevent 
tumour growth through a restoration of wild-type p53 activity. 
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We propose that ANKRD11 suppresses mutant p53 GOF by directly 
interacting with mutant p53 proteins resulting in a native wild-type p53 conformation 
(Fig. 6). This unique property of ANKRD11 is similar to that reported for small 
molecules and peptides PRIMA-1 (Bykov et al 2002) and CDB-3 (Friedler et al 2002, 
Issaeva et al 2003) which reportedly restore a native conformation to mutant p53. We 
also show that expression of the ANKRD11 ankyrin domain is sufficient to dissociate 
the p53-R175H•p63 and p53-R175H•p73 complexes (Fig. 7). The ability of mutant 
p53 to drive tumourigenesis is reported to be partially based on its ability to sequester 
the p63 and p73 proteins, thus disrupting their function to suppress metastasis (Di 
Como et al 1999, Gaiddon et al 2001). It is likely that ANKRD11 is suppressing 
mutant p53 GOF through an interaction with the C-terminus of p53 (Supp. Fig. S9) 
coupled with its ability to enhance the acetylation of the DNA binding domain 
(Neilsen et al 2008), thus leading to a stabilised, active conformation of p53 and 
subsequent dissociation of the mutant p53•p63/p73 complexes. Alternatively, the C-
terminus of p53 has been shown to be required for mutant p53 invasive activity 
(Muller et al 2009), therefore we speculate that ANKRD11 may be out competing the 
recruitment of another unknown oncogenic protein required for mutant p53 GOF. 
 
Studies defining mutant p53 interactions with p63 and p73 have included 
different subsets of mutants with the predominant focus on p53-R175H and p53-
R273H (Gaiddon et al 2001, Strano et al 2000, Strano et al 2002). In this study we 
present a comprehensive comparison of the interaction of eight p53 hotspot mutants 
with p63 and p73, and show the structural class of mutants preferentially interact with 
both p63 and p73 with R273H the only DNA contact  mutant shown to interact (Fig. 
7), which is consistent with previous studies (Gaiddon et al 2001, Strano et al 2002). 
 18
A previously reported interaction between p63 and R248W (Gaiddon et al 2001) was 
not observed in this study. These data and others suggest a correlation between the 
structural integrity of the p53 protein and its ability to interact with p63/p73 (Gaiddon 
et al 2001). Interestingly, the endogenous p53-R273H mutant is reported to be 
immunoprecipitated from cell lines with the mutant specific antibody, PAb240 
(Muller et al 2008), suggesting p53-R273H exhibits some structural perturbations. 
Furthermore, no interaction with p63 or p73 was observed for p53-R273C, suggesting 
that the amino acid at codon 273 plays an integral role in this interaction. In contrast 
to other structural mutants, G245S did not interact with p63 or p73 (Fig. 7). However, 
the p53-G245S protein is only local distorted in comparison to p53-R175H and p53-
R282W that are globally distorted (Brosh and Rotter 2009, Wong et al 1999). These 
findings suggest that the extent of mutant p53 protein distortion may also dictate its 
ability to sequester p63 and p73. 
 
The DNA contact mutants R248W and R248Q are shown to have a GOF in 
relation to multinucleation (Fig. 2A) and cellular morphology (Fig. 4A) respectively, 
however these mutants did not interact with p63 or p73. Therefore these mutants 
acquire their GOF independently of p63 or p73, presumably through interactions with 
other regulatory proteins. Possible candidates include the DNA repair complex 
protein MRE11. The specific interaction between MRE11 and the R248W mutant is 
reported to inactivate ATM, thereby inducing genetic instability (Liu et al 2010, Song 
et al 2007). 
 
This study provides novel insight into the complex oncogenic processes that 
are driven by mutant p53. The discovery of ANKRD11 as an endogenously expressed 
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protein with the capacity to suppress various mutant p53 functions as well as restore 
wild-type activity to p53 mutants, opens a novel avenue to indirectly restore tumour 
























Materials and Methods 
Cell Lines and Antibodies 
H1299, MDA-MB-231, MCF-7 and SK-BR-3 cells were maintained in 
DMEM or RPMI with 10% FCS. Ecdysone-inducible derivatives of the H1299 cells 
were generated by stable transfection of pVgRXR and selection in zeocin (Invitrogen, 
CA) at 100 µg/ml, followed by stable transfection of pI-TK-Hygro-p53-wt/mut 
plasmid linearised with XbaI and subsequent selection of clones in Hygromycin B 
(Sigma Aldrich, St. Louis, MO) at 600 µg/ml. Stable cell lines expressing GFP-
ANKRD11-Myc were generated through retroviral transduction using pLNCX2 
vector as described previously (Neilsen et al 2008) and selected in G418 (Invitrogen) 
at 500 µg/ml. Antibodies used were: mouse α-Myc, mouse α-FLAG, mouse α-p53 
DO-1 (Santa Cruz Biotechnology, Santa Cruz, CA), rat α-HA (Roche), rabbit α-β 
tubulin (Abcam), mouse α-β actin (Sigma Aldirch), mouse α-p21 (Thermo Scientific), 
mouse α-ZO-1 (Zymed), mouse α-Centrin, rabbit α-γ tubulin (Sigma), mouse α-
MPM2 (Upstate), α-mouse IgG HRP linked (GE Healthcare), α-rabbit IgG HRP 
linked (GE Healthcare), α-rat IgG HRP linked (Dako, Carpinteria, CA), mouse light 
chain specific HRP linked (Millipore, Temecula, CA).  
 
Plasmids 
To generate epitope tagged fragments of ANKRD11, specific regions of 
ANKRD11 were PCR amplified using primers 1 to 8 (Table S1) from pLNCX2-
ANKRD11-Myc (Neilsen et al 2008) and cloned in-frame into mammalian expression 
vectors pCMV-Tag2 or pCMV-Myc. Myc-p53-FL were generated as previously 
described (Neilsen et al 2008). Specific fragments of p53 were PCR amplified using 
primers 9 to 14 (Table S1) and cloned in frame into pCMV-Myc. Deletion constructs 
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of Myc-p53 were generated through overlap PCR using the primers 15 to 19 (Table 
S1). 
 
Breast tumour analysis, expression microarray analysis and real-time RT-PCR 
Breast tumour patient samples and real time PCR are as previously described 
(Kumar et al 2005, Pishas et al 2010). Expression profiling was performed using 
Affymetrix Human Gene 1.0 ST array as per manufacturer’s protocol. 
 
Co-Immunoprecipitation Assays 
H1299 cells (5×105) were seeded into 60 mm dishes and transfected with the 
indicated constructs using Lipofectamine 2000 (Invitrogen). For the interaction 
domain mapping studies, cells were collected 24 hours post-transfection, resuspended 
in lysis buffer 1 (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100) 
supplemented with 1× complete protease inhibitor cocktail (Roche), sonicated and 
centrifuged. Clarified lysates were incubated with FLAG-M2 agarose (Sigma) for 2 
hours at 4ºC with rotation. Beads were washed twice with lysis buffer 1, twice with 
wash buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS) and twice with 20mM Tris-HCl pH 7.5. Protein complexes 
were eluted with FLAG peptide (200 ng/mL). For the p63/p73 interaction studies, 
cells were sequentially transfected with the indicated plasmids and harvested 48 hours 
post-transfection in 300μL lysis buffer 2 (20 mM Tris-HCl pH 8, 1 mM EDTA, 0.5% 
NP-40, 150 mM NaCl, 1 mM DTT, 10% glycerol), sonicated and centrifuged. 
Clarified lysates were incubated with 200 ng α-p53 (DO-1) for 1 hour at 4ºC with 
rotation, followed by addition of 10 μL Protein G sepharose beads (GE Healthcare) 
for 1 hour. Beads were washed four times with 400 μL lysis buffer 2 and protein 
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complexes were eluted with 1×SDS loading buffer at 95ºC for 5 min. Western blot 
analysis of inputs and co-immunoprecipitated protein complexes was performed as 
described previously (Kumar et al 2005). 
 
Centrosome defects and multinucleation assays 
To measure centrosome defects, unsynchronised cells were plated at 10% 
confluency and treated with 2.5 μg/mL PonA for the indicated times. Multinucleation, 
number of centrosomes and centrosome size was measure in interphase cells. Distance 
between centrosomes was measured in S and G2 cells. 50 cells were counted per 
condition. For mitotic assays, cells were plated at 10% confluency, synchronised by 
double thymidine block and harvested at 11 hours post-release. 2.5 μg/mL PonA was 
added 24 hours before harvesting. 100 cells were counted per condition. 
 
Colony development assays 
EI p53-mut cell lines were treated with or without 2.5 μg/mL PonA for 72 hrs. 
Cells were subsequently collected and plated in duplicate in a 6-well format at 1000 
cells/well in DMEM ± PonA. Cells were grown for 10 days, fixed for 5 minutes with 




For ZO-1 staining,  2000 cells were plated on glass coverslips in a 6-well and 
allowed to form small colonies of 4-6 cells (~2 days). PonA was added to wells at a 
final concentration of 2.5 μg/mL for 0, 16 or 40hrs. IF protocols were based on those 
previously described (Neilsen et al 2008).  
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For mitotic staining, cells were synchronised by addition of 2.5 mM thymidine 
for 16 hours then washed three times in PBS. Cells were incubated for a further 10 
hours before the thymidine block was repeated. Cells were fixed with ice-cold 
methanol at 11 hours post-release from the second thymidine block.  PonA was added 
at 24 hours prior to harvesting. Where metaphase cells were required 10 μM MG132 
was added at two hours prior to harvesting. Cells were blocked in 3% BSA in PBS for 
20 minutes followed by incubation with the indicated antibodies in 03% BSA/PBS 
solution (30 minutes, RT), and incubation with the indicated Alexa-Fluor-conjugated 
secondary antibodies (30 minutes, RT). Coverslips were mounted in mowiol 
containing 2.5% DABCO. Cells were visualised using a DeltaVision personal DV 
deconvolution microscope. Images underwent restoration deconvolution and were 
analysed using softWoRx version 3.6.1. Fluorescent images represent projections of 




Real-time invasion assays were performed using the xCelligence Real-Time 
Cell Analyzer (RTCA) DP (Roche), as per the manufacturer’s protocol. Ecdysone-
inducible H1299 derivatives, EI-H1299-p53-R175H or EI-H1299-p53-R175H-
ANKRD11 were grown in the presence or absence of PonA at 2.5μg/ml for 24 hours. 
Following induction, sub-confluent cell cultures were collected in serum free media 
and plated at 2×104 cells per well in the top chamber of a CIM-Plate 16 pre-coated 
with 5% Matrigel (BD Biosciences, San Jose, CA). DMEM containing 10% FCS was 
used as a chemo-attractant. Real-time migration assays were performed using 
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Incucyte (Essen). Phase images were taken every 30 minutes and wound closure and 
cell confluence calculated using specific Incucyte software. 
 
Live cell imaging 
Live cell imaging was conducted using a DeltaVision Core microscope using 
softWoRx version 3.6.1. Cells were plated at 10% confluency, synchronised by 
double thymidine block and 2.5 μg/mL PonA added 24 hours before imaging. Bright 




 Significance testing for breast tumour data was performed using a two-tailed 
Student’s t-test. Two-Way ANOVA and Bonferroni posttests were performed using 
GraphPad Prism (v5, CA, USA). 
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Figure 1. ANKRD11 is down-regulated in breast tumours and is predictive of 
poor clinical outcome 
A: ANKRD11 expression levels were determined by quantitative real-time PCR in 38 
breast tumours and 2 normal breast tissues. 
B: Kaplan-Meier curves derived from publically available survival data associated 
with a cohort of 246 breast cancer patients with known p53 status (GSE3494; (Miller 
et al 2005)). Expression of ANKRD11 was sourced from expression microarray 
analyses. Tumours were ranked by ANKRD11 expression, with the lowest 15% of 
these tumours defined as ‘Low ANKRD11’. 
C: Two-by-two test (Fisher’s exact test) showing a correlation between lymph node 
status of a cohort of 53 patients with mutant p53 expressing breast tumours 
(GSE3494; (Miller et al 2005)) and ANKRD11 expression (as defined in B). 
 
Figure 2. Mutant p53 expression promotes multinucleation and centrosome 
abnormalities that are suppressed by ANKRD11 
EI p53-WT, EI p53-R248W, EI p53-R175H, EI p53-R249S and EI p53-R175H-
ANKRD11 were plated at 10% confluency and treated with 2.5μg/mL PonA for 0, 24, 
48, 72 or 96 hours. Multinucleation and centrosome characteristics were subsequently 
analysed. γ-tubulin was used as a centrosome marker for centrosome measurements. 
Error bars represent the SEM of three independent experiments; * p < 0.05, ** p < 
0.01 and *** p < 0.001. 
A: The percentage of multinucleated cells was determined using DAPI and α-tubulin 
staining. For each experiment 100 cells were counted per condition. 
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B: The average number of centrosomes per cell was determined in wt and p53 
mutants at 24 hour intervals over 96 hours. For each experiment 40 cells were counted 
per condition. 
C: The average centrosome size was determined in wt and p53 mutants at 24 hour 
intervals over 96 hours. For each experiment 40 cells were counted per condition. 
Where two or more centrosomes were present the largest centrosome was measured. 
D: The average distance between centrosomes was determined in wt and p53 mutants 
at 24 hour intervals over 96 hrs. For each experiment 40 cells were counted per 
condition. Where three or more centrosomes were present the largest distance 
between two neighbouring centrosomes was measured. 
E: The level of wild-type or p53-R175H protein expressed following 24 hour 
induction in the presence or absence of ANKRD11 re-expression was determined by 
western blot analysis, with β-actin protein levels used as a loading control. 
 
Figure 3. Induction of mutant p53 results in mitotic defects that are alleviated by 
ANKRD11 expression 
EI p53-R248W, EI p53-R175H, EI p53-R249S and EI p53-R175H-ANKRD11 cells 
were plated at 10% confluency and synchronised by double thymidine block and 
harvested at 11 hours post-release. PonA was added at 24 hours before harvesting. For 
each experiment 100 cells were counted per condition. Error bars represent the SEM 
from three independent experiments; * p < 0.05, ** p < 0.01 and *** p < 0.001. 
A: The average percentage of metaphase cells with abnormal spindles was determined 
using α-tubulin as a marker of the mitotic spindle. Cells were synchronised in 
metaphase by the addition of 10 μM MG132 at two hours prior to harvesting. 
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B: Representative images of the spindle morphology uninduced and induced cells. 
Cells were stained for α-tubulin (red), γ-tubulin (green) and DAPI (blue). Scale bar 
represents 20 μm. 
C: The average percentage of anaphase/telophase cells with lagging chromosomes 
was determined using DAPI as a marker of the DNA. 
D: The average percentage of daughter (newly divided) cells with anaphase bridges 
was determined using DAPI as a marker of the DNA. 
E: The average time taken for cells to undergo mitosis. Synchronised cells were 
followed by time lapse microscopy and imaged every five minutes. Time in mitosis 
was defined as the time from nuclear envelope breakdown until the point at which two 
daughter cells could be seen. For each experiment 50 cells were counted per 
condition. 
 
Figure 4. Induction of mutant p53 in H1299 cells results in an altered cellular 
phenotype, which is suppressed by ANKRD11 
A: EI p53-R175H and EI p53-R248Q cells were untreated (left) or treated (middle) 
with 2.5 μg/mL PonA and plated at single cell density. Colonies were fixed and 
stained 10 days post-plating. Pictures show representative colonies. Each cell line 
with re-expressed ANKRD11 was treated in a similar manner (right). 
B: The EI p53-R175H cell line were seeded at single cell density and allowed to 
develop into colonies for 72 hours prior to the addition of PonA (2.5 μg/mL) as 
indicated. Colonies were stained for the presence of cell-cell junctions, as indicated by 
ZO-1 staining (red). 
 
Figure 5. ANKRD11 suppresses p53-R175H mediated invasion 
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A: EI p53-R175H or EI p53-R175H-ANKRD11 cells were treated as indicated with 
2.5 μg/mL PonA for 24 hrs prior to plating in the upper chamber of a CIM-16 plate 
coated with 5% matrigel. Real-time invasion of cells was measured on an Xcelligence 
RTCA DP analyser. 
B: The rate of invasion during the linear phase (between 15 and 24 hours) as 
determined by the gradient (n=4; * p<0.05). 
 
Figure 6. ANKRD11 restores a native conformation to a p53 mutant 
A: H1299 cells were sequentially transfected with 4 μg FLAG-ANKRD11144-288aa and 
0.5 μg wild-type or mutant p53 expression constructs, followed by 
immunoprecipitation with an α-FLAG antibody. Inputs and immunoprecipitated 
complexes were subjected to western blot analysis with α-p53 and α-FLAG 
antibodies. All p53 mutants investigated are shown to co-precipitate with 
ANKRD11144-288aa above the level of non-specific, background levels seen in empty 
vector control lanes. 
B: EI p53-R175H and EI p53-R175H-ANKRD11 cells were treated with 2.5 μg/mL 
PonA for 24 hours, immunoprecipitated with indicated antibody and detected by 
western blot analysis using α-p53 (DO-1) and α-mouse light chain-specific secondary 
antibody. 
 
Figure 7. The ankyrin domain of ANKRD11 dissociates the p53-R175H•p63/p73 
complexes 
A: H1299 cells were co-transfected with 2 μg wild-type or mutant p53 expression 
constructs and 4 μg HA-p63. Cellular extracts were subjected to immunoprecipitation 
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with α-p53 (DO-1) antibody. Inputs and immunoprecipitates were subjected to 
western blot analysis using α-p53 and α-HA antibodies. 
B: Cells were treated as described above (A) but p53 was co-transfected with HA-
p73. 
C: H1299 cells were sequentially transfected with 2 μg p53-R175H, 4 μg HA-p63 and 
2 μg various Myc-ANKRD11 fragment expression constructs as indicated followed 
by immunoprecipitation with α-p53 (DO-1) antibody. Inputs and immunoprecipitates 
were subjected to western blot analysis with α-p53, α-Myc and α-HA antibodies. The 
amount of p63 co-precipitated with p53-R175H was determined by densitometry. 
D: Cells were treated as above (C) but with HA-p73 and Myc-ANKRD11144-288aa  
expression constructs. 
E: Schematic diagram illustrating the region of ANKRD11 capable of dissociating the 
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